Trials / Completed
CompletedNCT00136942
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 370 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin |
Timeline
- Start date
- 2005-04-01
- First posted
- 2005-08-29
- Last updated
- 2021-02-18
Locations
20 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00136942. Inclusion in this directory is not an endorsement.